GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Reviva Pharmaceuticals Holdings RVPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.31

+10.21%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Reviva Pharmaceuticals Holdings — daily RVPH Delayed
Market value
$1.1m
Last close × shares
Volume
14.6k
Shares, 20 Nov 2026

About Reviva Pharmaceuticals Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Reviva Pharmaceuticals Holdings is based in Cupertino, California and is incorporated in Delaware. Its shares trade on OTC under the ticker RVPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $19.9m. At that date it held total assets of $15.9m and shareholders' equity of $8.6m.

In its own words

All references in this report to “Reviva,” the “Company,” “we,” “us,” or “our” mean Reviva Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.

Old Reviva was incorporated in the state of Delaware on May 1, 2006, and its subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., was incorporated on December 23, 2014. Tenzing was formed pursuant to the laws of the British Virgin Islands on March 20, 2018.

We are a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burdens to society, patients, and their families. Our current pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. We use a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208 (Figure 1). Both are new chemical entities discovered in-house. We have been granted composition of matter patents for both brilaroxazine and RP1208 in the United States (U.S.), Europe, and several other countries.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

More about Reviva Pharmaceuticals Holdings →

Latest on Reviva Pharmaceuticals Holdings

Our reporting

We have not reported on Reviva Pharmaceuticals Holdings yet.

Next results

29 Mar 2027

Due on 29 Mar 2027. Analysts expect earnings of -0.41 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Reviva Pharmaceuticals Holdings's ticker?

Reviva Pharmaceuticals Holdings trades as RVPH on its US listing, under ISIN US76152G2093.

What was Reviva Pharmaceuticals Holdings's last closing price?

0.31 on 20 Nov 2026. The figure is in USD and is never converted.

When does Reviva Pharmaceuticals Holdings next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.